AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation
- 26 February 2021
- journal article
- editorial
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 22 (7), 783-795
- https://doi.org/10.1080/14656566.2021.1882995
Abstract
To date, there is no FDA-approved treatment for agitation in Alzheimer’s disease (AD). Medications currently used off-label have modest clinical efficacy and serious side effects. The authors review the pharmacology, mechanism of action, pharmacokinetics, efficacy, safety and tolerability data of AVP-786, for the treatment of agitation in AD. AVP-786, the deuterated form of dextromethorphan/quinidine (AVP-923) which is an approved treatment for Pseudo-Bulbar Affect, emerges as a promising and safe treatment for agitation in AD. Deuteration is an innovative technology that accelerates drug development by conducting faster and less costly clinical trials. No phase II trial was conducted with AVP-786 for the treatment of agitation in AD; the decision to expedite the development of this drug was based on a successful phase II study with AVP-923. Phase III trials with AVP-786 (TRIAD-1 and TRIAD-2) showed mixed findings probably due to the difference in study design. Future phase III studies should use innovative study designs such as the Sequential Parallel Comparison Design to mitigate high placebo response, and the Cohen-Mansfield Agitation Inventory for agitation assessment. They should also include positron emission tomography studies to assess occupancy of various receptors in the brain after AVP-786 is administered.Keywords
This publication has 67 references indexed in Scilit:
- Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: Application to antidepressant trialsClinical Trials, 2012
- Neuropsychiatric Symptoms and the Risk of Institutionalization and Death: The Aging, Demographics, and Memory StudyJournal of the American Geriatrics Society, 2011
- Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness TrialAmerican Journal of Psychiatry, 2008
- Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County StudyInternational Journal of Geriatric Psychiatry, 2007
- Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's DiseaseThe New England Journal of Medicine, 2006
- Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosisAnnals of Neurology, 2006
- The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via σ 1 receptor activation: comparison with the effects of dextromethorphanBritish Journal of Pharmacology, 2005
- Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor MetabolizersThe Journal of Clinical Pharmacology, 2004
- The antitussive effect of dextromethorphan in relation to CYP2D6 activityBritish Journal of Clinical Pharmacology, 1999
- Dextromethorphan An Overview of Safety IssuesDrug Safety, 1992